Biomarker and Diagnostic Assay Development Services for Diabetic Cardiovascular Complications
Early diagnosis and biomarker development are key to improving the prognosis of cardiovascular complications in diabetes. Ace Therapeutics delivers end-to-end biomarker and diagnostic development services, driving preclinical translation of novel diagnostic strategies through multi-omics and validated models.
Key Challenges in Diagnosis and Biomarker Development for Diabetic Cardiovascular Complications
The diagnosis of diabetes and its cardiovascular complications currently faces the following bottlenecks:
- Insufficient sensitivity for early diagnosis: Traditional biomarkers (such as cTnI and BNP) struggle to detect subtle cardiovascular damage during the early stages of disease progression.
- Limited biomarker specificity: Fluctuations in blood glucose and renal dysfunction may interfere with accurate interpretation of biomarkers.
- Complex translation pathway: From the discovery of candidate biomarkers to the implementation of clinical diagnostic tools, it requires navigating multiple stages including analytical validation, technical platform adaptation, and regulatory approval.
Our Biomarker and Diagnostic Assay Development Services for Diabetic Cardiovascular Complications
Leveraging our established disease models and multi-omics analysis capabilities in diabetic cardiovascular complications, we provide end-to-end solutions from novel biomarker discovery and validation to diagnostic assay development.
Biomarker Development Services
| Services |
Description |
Technology |
| Potential Biomarkers Screening |
Support for biomarker screening using model animal-derived biospecimens (serum/plasma, cardiac/vascular tissues, cerebrospinal fluid). |
Integrated proteomics (TMT/iTRAQ), metabolomics (LC-MS/MS), microRNA sequencing, exosome molecular profiling, and single-cell sequencing for systematic identification of differentially expressed biomolecules. |
| Biomarker Validation and Confirmation |
Phased biomarker validation using in vivo models: preliminary validation, specificity verification, and clinical relevance assessment. |
Establish quantitative detection methods including ELISA, Western Blot, qPCR, and immunohistochemistry, optimizing detection sensitivity, specificity, and linear range. |
Diagnostic Method Development Services for Diabetes and Its Cardiovascular Complications
| Services |
Description |
| Molecular Diagnostics Development |
Development of detection panels for exosomal miRNAs, and protein biomarkers utilizing blood, saliva, and other biospecimens. |
| Radiomics Biomarker Development |
Integrate high-frequency ultrasound, micro-CT, and optical imaging in small animals to quantify cardiovascular structural and functional parameters (such as left ventricular ejection fraction and vascular plaque volume) for the development of novel imaging biomarkers. |
| Tailored Development Services |
Client-specific development of dedicated single-marker tests or comprehensive multi-marker profiling solutions. |
Our Advanced Technology Platform
- Multi-omics integration analysis platform: Integrates spatial transcriptomics and proteomics technologies to in situ decipher molecular expression networks within cardiovascular tissues.
- High-sensitivity detection platform: Employs single-molecule immunoassay, digital PCR, and other techniques to achieve precise quantification of trace biomarkers.
- AI-assisted data analysis platform: Utilizes deep learning models to mine high-dimensional data and predict dynamic correlations between biomarkers and disease progression.
Advancing diagnostic strategies for diabetic cardiovascular complications requires robust biomarker science. Contact our biomarker development team to discuss how our integrated platforms can support your specific program goals.
All of our services and
products are intended for preclinical research use only and cannot be used to diagnose, treat or
manage patients.
Related Services
Related Products
